Nucleoside hydrolase urate oxidase combined engineering bacterium and construction method thereof

By constructing a combined engineering bacteria of nucleoside hydrolase and uric acid oxidase, the problem of lack of both nucleoside hydrolase and uric acid oxidase in the existing technology is solved, and the efficient degradation of uric acid and inosine is achieved, and new high uric acid is provided. treatment plan for vasemia.

CN118979071APending Publication Date: 2024-11-19XIAMEN TREATGUT BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411051226.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The lack of engineered bacteria containing both nucleoside hydrolase and uric acid oxidase in the prior art makes it difficult to effectively degrade uric acid and inosine, resulting in poor therapeutic effect of hyperuricemia.

Method used

By constructing a combined engineering bacteria of nucleoside hydrolase and uric acid oxidase, the nucleoside hydrolase and uric acid oxidase genes are integrated into the same strain using codon optimization, homologous recombination and CRISPR/Cas9 system to form a UOX-rihC strain, achieving the Synergistic degradation of uric acid and inosine.

Benefits of technology

The efficient degradation of uric acid and inosine is achieved, and the inosine degradation effect of the combined strain is better than that of single-gene strain mixing, providing a new treatment plan for hyperuricemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979071A_ABST
    Figure CN118979071A_ABST
Patent Text Reader

Abstract

The invention provides a nucleoside hydrolase urate oxidase combined engineering bacterium and a construction method thereof, and the construction method comprises the following steps: S1, carrying out codon optimization on a nucleoside hydrolase rihC gene sequence, and the optimized sequence is as shown in SEQ ID NO: 37; s2, carrying out homologous recombination on the optimized nucleoside hydrolase rihC gene sequence and a pLPP-OmpA plasmid vector, and constructing an LPrihC plasmid; and S3, transforming the LPrihC plasmid into a urate oxidase engineering bacterium, and constructing the nucleoside hydrolase and urate oxidase combined engineering bacterium. When expression protein genes of urate oxidase and nucleoside hydrolase are constructed on the same strain, uric acid and inosine can be degraded, and the inosine degradation effect of the combined strain is superior to that of a single-gene strain mixture.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a nucleoside hydrolase uricase combined engineering bacterium and a construction method thereof, belonging to the technical field of microorganisms. Background Art

[0002] Hyperuricemia refers to the supersaturation of urate in the extracellular fluid. It is generally considered that blood urate is ≥417 μmol·L -1 Hyperuricemia should be considered when treating gout. Hyperuricemia is an important biochemical basis of gout, but hyperuricemia is not equal to gout. Gout is related to the level of uric acid concentration and the length of time of accumulation. The higher the uric acid value or the longer the duration, the more likely it is to suffer from gout. Gout is a chronic disease caused by the deposition of sodium urate crystals. It usually manifests as acute, self-limiting inflammatory monoarthritis, affecting the joints of the lower limbs. Clinically, gout is mainly manifested as recurrent acute gouty arthritis, chronic gouty arthritis, tophi, uric acid stones, uric acid nephropathy, etc. Elevated serum uric acid levels are the main risk factor for monosodium urate (MSU) crystal deposition and the development of gout. The use of uric acid-lowering therapy to continuously lower serum uric acid levels is crucial for the long-term management of gout. Its purpose is to dissolve MSU crystals, inhibit gout attacks and resolve tophi.

[0003] Nucleoside hydrolases (rihC, EC3.2.2.-), which degrade extracellular nucleosides to nucleobases, reduce the concentration of urate precursors in the gastrointestinal tract. Nucleobases are absorbed less by the intestinal epithelium than by nucleosides. In cases of nucleobase malabsorption, the presence of fewer nucleobase-specific transporters in the intestinal epithelium may be important. The reduced nucleoside content and the limited absorption of converted nucleobases by the intestine may affect the expression of purine nucleoside phosphorylase (PNP) and xanthine oxidase (XOD) and their reduced enzymatic activities and lead to a decrease in the uric acid concentration in the blood.

[0004] Urate oxidase (EC1.7.3.3), also known as uricase, is an oxidase in the purine metabolic pathway in organisms. It is widely distributed in various species in nature and mainly mediates the enzymatic reaction of oxidative degradation of uric acid. It can degrade uric acid into water-soluble small molecules allantoin that are more easily excreted by the kidneys. It is of great significance to construct engineered bacteria containing both nucleoside hydrolases and uricases for the prevention and treatment of hyperuricemia. However, at present, there is no report on engineered bacteria containing both nucleoside hydrolases and uricases in the prior art. Summary of the invention

[0005] The present invention provides a nucleoside hydrolase uricase combined engineering bacterium and a construction method thereof, which can effectively solve the above problems.

[0006] The present invention is achieved in that:

[0007] A method for constructing a nucleoside hydrolase uricase combined with an engineered bacterium comprises the following steps:

[0008] S1, codon optimization of the nucleoside hydrolase rihC gene sequence, the optimized sequence is as shown in SEQ ID NO: 37;

[0009] S2, homologous recombination of the optimized nucleoside hydrolase rihC gene sequence with the pLPP-OmpA plasmid vector to construct the LPrihC plasmid;

[0010] S3, transforming the LPrihC plasmid into uricase oxidase engineering bacteria to construct the nucleoside hydrolase uricase oxidase combined engineering bacteria.

[0011] In some embodiments, the optimized nucleoside hydrolase rihC gene sequence has a BamHI restriction site at the 5' end and a histidine tag (6×His-Tag) and a HindIII restriction site at the 3' end.

[0012] In some embodiments, the method for constructing the uricase engineering bacteria comprises the following steps:

[0013] (1) The sequence of the urate oxidase encoding gene UOX was codon optimized, and the sequence was shown in SEQ ID NO:4; the sequence of the signal peptide PelB was optimized, and the optimized sequence was shown in SEQ ID NO:3;

[0014] (2) Using overlapping PCR technology to construct the urate oxidase expression cassette;

[0015] (3) The CRISPR / Cas9 system is used to integrate the uricase expression frame into the genome of the chassis strain to construct the uricase oxidase engineered bacteria.

[0016] In some embodiments, the chassis strain is EcN bacteria.

[0017] In some embodiments, the site where the uricase expression cassette is integrated into the genome of the chassis strain EcN bacteria is the non-coding region between uspG and rnk (689269-689288) and the non-coding region between pntA and ydgH (1766918-1766937).

[0018] In some embodiments, the promoter for constructing the uricase expression cassette is P32, whose sequence is shown in SEQ ID NO:2, and the terminator is T1, whose sequence is shown in SEQ ID NO:5.

[0019] A nucleoside hydrolase and uricase combined engineering bacteria constructed by the above method.

[0020] A use of the above-mentioned nucleoside hydrolase urate oxidase combined with engineered bacteria in the preparation of a drug for treating hyperuricemia.

[0021] The beneficial effects of the present invention are:

[0022] When the expression protein genes of urate oxidase and nucleoside hydrolase are constructed on the same strain, both uric acid and inosine can be degraded. In the combined strain UOX-rihC, the UOX gene and rihC can play a synergistic role and jointly improve the degradation rate of inosine, so that the inosine degradation effect of the combined strain UOX-rihC is better than that of a mixture of single-gene strains. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 It is a technical roadmap of an embodiment of the present invention.

[0025] Figure 2 This is the pEcgRNA-N20[PelB-UOX] vector map of the embodiment of the present invention.

[0026] Figure 3 FIG. 1 is a diagram of a rihC gene fragment amplified by PCR according to an embodiment of the present invention.

[0027] Figure 4 1 is a diagram of the LPrihC vector construction of an embodiment of the present invention.

[0028] Figure 5 This is the LPrihC vector map of the embodiment of the present invention.

[0029] Figure 6 1 is a colony morphology diagram of the LPrihC strain according to an embodiment of the present invention.

[0030] Figure 7 This is a diagram of Western-blot identification of recombinant nucleoside hydrolase expression in an embodiment of the present invention.

[0031] Figure 8 This is a protein spectrum of the LPrihC strain nucleoside hydrolase purified by chromatography according to an embodiment of the present invention.

[0032] Fig. 9 It is a protein spectrum of the wild-type EcN strain nucleoside hydrolase purified by chromatography according to an embodiment of the present invention.

[0033] Fig.10 This is a diagram showing the effect of protein purification identified by Coomassie Brilliant Blue staining in an embodiment of the present invention.

[0034] Fig.11 It is a diagram showing the effect of Western-blot identification of protein purification in an embodiment of the present invention.

[0035] Fig.12 It is a diagram showing the nucleoside degradation effect of the recombinant nucleoside hydrolase protein rihC according to an embodiment of the present invention.

[0036] Fig.13 This is a graph showing the results of measuring the inosine content of inosine degradation by the recombinant nucleoside hydrolase protein rihC according to an embodiment of the present invention.

[0037] Fig.14 This is a graph showing the results of measuring the guanosine content in guanosine degradation by the recombinant nucleoside hydrolase protein rihC according to an embodiment of the present invention.

[0038] Fig.15 This is a graph showing the results of measuring the inosine content in whole-cell nucleoside degradation of the engineered bacteria UOX-rihC of an embodiment of the present invention.

[0039] Fig.16 This is a graph showing the results of measuring guanosine content in whole-cell nucleoside degradation of the engineered bacteria UOX-rihC of an embodiment of the present invention.

[0040] Fig.17 This is a diagram showing the uric acid degradation effect of the whole cell of the engineered bacteria UOX-rihC according to an embodiment of the present invention.

[0041] Fig.18 It is a comparison chart of the inosine degradation effects of the engineered bacteria UOX-rihC and the single-gene strain LPrihC according to the embodiment of the present invention. DETAILED DESCRIPTION

[0042] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0043] A method for constructing a nucleoside hydrolase uricase combined with an engineered bacterium comprises the following steps:

[0044] S1, codon optimization of the nucleoside hydrolase rihC gene sequence, the sequence is shown in SEQ ID NO: 37; after codon optimization, the protein can be better expressed in Escherichia coli, and the gene expression level is improved;

[0045] S2, homologous recombination of the optimized nucleoside hydrolase rihC gene sequence with the pLPP-OmpA plasmid vector to construct the LPrihC plasmid; the pLPP-OmpA expression vector uses the E. coli strong promoter lpp and the OmpA secretion signal peptide, which can effectively construct a vector for expressing the recombinant nucleoside hydrolase;

[0046] S3, transforming the LPrihC plasmid into uricase oxidase engineering bacteria to construct the nucleoside hydrolase uricase oxidase combined engineering bacteria.

[0047] The nucleoside hydrolase-uricase oxidase combined with engineered bacteria constructed in the embodiment of the present invention can degrade inosine and guanosine, convert nucleosides into difficult-to-absorb nucleobases, thereby reducing the intestinal absorption of nucleosides, and can also degrade uric acid, thereby leading to a decrease in the concentration of uric acid in the blood. The application of nucleoside hydrolase-uricase oxidase combined with engineered bacteria to the intestine has positive significance for the treatment of hyperuricemia.

[0048] In some embodiments, the optimized nucleoside hydrolase rihC gene sequence has a BamHI restriction site at the 5' end and a histidine tag (6×His-Tag) and a HindIII restriction site at the 3' end, which facilitates homologous recombination by enzyme digestion of the pLPP-OmpA vector to construct a LPrihC strain expressing the nucleoside hydrolase.

[0049] In some embodiments, the method for constructing the uricase engineering bacteria comprises the following steps:

[0050] (1) The sequence of the uricase oxidase encoding gene UOX is codon-optimized, and the sequence is shown in SEQ ID NO:4; the sequence of the signal peptide PelB is optimized, and the optimized sequence is shown in SEQ ID NO:3; the uricase oxidase encoding gene UOX is derived from the utilis Candida utilis Cyberlindnera jadinii, and its sequence is codon-optimized according to codon preference and GC content. Since the codon preference in the protein translation process between different species is an important factor affecting the protein expression amount, UOX can better express protein in Escherichia coli after codon optimization, thereby improving the gene expression level; after the signal peptide is optimized, a better secretion effect is achieved, and the formation of inclusion bodies is avoided;

[0051] (2) Using overlapping PCR technology to construct the urate oxidase expression cassette;

[0052] (3) The CRISPR / Cas9 system is used to integrate the uricase expression frame into the genome of the chassis strain to construct the uricase oxidase engineered bacteria.

[0053] In some embodiments, the chassis strain is EcN bacteria.

[0054] In some embodiments, the site where the uricase expression frame is integrated into the genome of the chassis strain EcN bacteria is the non-coding region between uspG and rnk (689269-689288) and the non-coding region between pntA and ydgH (1766918-1766937). The above-mentioned uricase gene fragment integrated at two sites can effectively increase the total expression of recombinant uricase, effectively improving the uric acid degradation effect.

[0055] In some embodiments, the promoter for constructing the uricase expression cassette is P32, whose sequence is shown in SEQ ID NO: 2, and the terminator is T1, whose sequence is shown in SEQ ID NO: 5. The promoter P32 can effectively initiate the transcription process of the uricase gene, so that the uricase oxidase can be synthesized in the cell. The terminator T1 terminates the transcription process at an appropriate time to ensure that the expression product of the uricase gene is not produced indefinitely.

[0056] A nucleoside hydrolase and uricase oxidase combined engineering bacteria constructed by the above method. A use of the nucleoside hydrolase and uricase oxidase combined engineering bacteria in the preparation of a drug for treating hyperuricemia.

[0057] Example 1 Construction of EcN[PelB-UOX-2] strain

[0058] 1. Overlapping PCR to construct the urate oxidase expression cassette [PelB-UOX]

[0059] The uricase expression cassette is composed of the following six fragments: upstream homologous fragment up, promoter P32, signal peptide PelB, uricase oxidase UOX (containing 6×His-Tag tag), terminator T1, and downstream homologous fragment down. The upstream homologous fragment (343bp) and the downstream homologous fragment (330bp) were consistent with the upstream and downstream genes of the non-coding region (689269-689288) site (TAAGAGCAAAATGATAAATCTGG) inserted between the genomic N20 target site uspG and rnk, and were amplified using the EcN genome as a template; the constitutive promoter P32 was a synthetic sequence (179bp); the signal peptide PelB was 66bp in total and was a synthetic sequence, and its amino acid sequence was optimized from "MKYLLPTAAAGLLLLAAQPAMA" to "MKYLLPTAAADLLLLAAQPAMA", that is, the 11th amino acid was mutated from glycine to aspartic acid, and the gene sequence was mutated from "GGT" to "GAT" to achieve better secretory expression; urate oxidase UOX was derived from Candida utilis Cyberlindnera jadinii (GenBank: D32043.1), a histidine tag (6×His-Tag) was added to the 3' end after codon optimization, a total of 930 bp; the addition of the histidine tag at the 3' end is to be able to identify the recombinant protein and extract the target protein during the identification of the recombinant protein, and the histidine tag structure is small and is less likely to affect the function of the fusion protein. The terminator T1 is a synthetic sequence. The above gene sequences and amplification primers are shown in Tables 1 and 2. All gene synthesis was completed by Sangon Biotech (Shanghai) Co., Ltd.

[0060] 2×Platinum TM SuperFi TM IIPCR Master Mix high-fidelity enzyme was used to amplify each fragment first, and then the [PelB-UOX] expression frame up-P32-PelB-UOX-T1-down was obtained by overlapping PCR amplification. The amplified product was purified using the full-form gold DNA gel rapid purification kit.

[0061] Table 1 Sequences of each fragment of [PelB-UOX] expression cassette

[0062]

[0063]

[0064] Table 2 Amplification primers

[0065]

[0066] 2. Construction of pEcgRNA-N20[PelB-UOX] vector

[0067] In order to insert the urate oxidase expression cassette into the EcN genome (GenBank: NZ_CP022686.1), the CRISPR target N20 (TAAGAGCAAAATGATAAATCTGG) was designed in the non-coding region between uspG and rnk (689269-689288) and T4 ligated with the pEcgRNA vector. The specific implementation is: the pEcgRNA vector is digested with BsaI restriction endonuclease, and the CRISPR N20 target primers are designed as UOX-N20-F (SEQ ID NO: 20) and UOX-N20-R (SEQ ID NO: 21), annealed to form a double strand, and T4 ligated with the pEcgRNA BsaI digested vector, and the pEcgRNA-N20 vector is obtained after positive clone screening and sequencing verification.

[0068] The pEcgRNA-N20 vector was double-digested with HindIII-HF restriction endonuclease and XhoI restriction endonuclease, and the [PelB-UOX] expression frame overlapping PCR product was homologously recombined with the pEcgRNA-N20 restriction vector using the Tiangen EasyGeno Assembly Cloning Kit homologous recombination kit, and the DH5α competent cells were transformed. The positive clones were preliminarily verified by colony PCR, and amplified using 2×Taq PCR Master Mix. The negative control was an empty pEcgRNA-N20 vector, and the amplification primers were PelB-F (SEQ ID NO: 11) and UOX-R (SEQ ID NO: 14). The positive clones picked by colony PCR were extracted from plasmids for plasmid size verification, and the positive clones with the correct size were digested with HindIII-HF restriction endonuclease. The plasmids with the correct digestion verification were sent to Qingke Bio for sequencing, and the sequencing results were compared and analyzed using Sequencher software.

[0069] 3. EcN[PelB-UOX] and strain construction.

[0070] The pEcCas plasmid was transformed into EcN bacteria to obtain the EcN (containing pEcCas plasmid) strain. The urate oxidase expression cassette [PelB-UOX] CRISPR was inserted into the genome: EcN (containing pEcCas plasmid) and strains were prepared into competent cells, and pEcgRNA-N20 [PelB-UOX] plasmid was transformed respectively, and spread on LB (Kana + Spec + ) medium, and single colony clones were picked for colony PCR verification, with primers T1-F (SEQ ID NO: 15) and UOX-EcN-R (SEQ ID NO: 19).

[0071] Eliminate the pEcgRNA-N20[PelB-UOX] plasmid: Select the positive clone in which the urate oxidase expression cassette [PelB-UOX] CRISPR is inserted into the EcN genome, i.e., the EcN[PelB-UOX] strain, and inoculate it into LB (Kana + ) + Rhamnose (final concentration 12 mM) in liquid culture, cultured in a shaking incubator at 37°C, 200 rpm for 12 h; the bacterial solution was diluted 40× and spread on LB (Kana + ) medium, and cultured in a 37°C incubator for 12 h. Single clones were picked and inoculated into LB (Kana + )、LB(Kana + Spec + ) culture medium midpoint plate verification and observe the colony growth.

[0072] Eliminate pEcCas plasmid: Pick LB (Kana + Spec + ) medium, inoculate the clones that do not grow in LB + Glucose (5g / L) liquid culture, and culture them in a shaking incubator at 37°C and 200rpm for 12h. Dilute the bacterial liquid 40× and spread it on LB + Glucose (5g / L) + Sucrose (12g / L) medium, and culture it in a 37°C incubator for 12h. Pick a single clone colony and inoculate it into LB, LB (Kana + )、LB(Spec + ) culture medium midpoint plate verification and observe the colony growth.

[0073] Inoculate the EcN[PelB-UOX] cells that have been depleted of pEcgRNA-N20[PelB-UOX] plasmid and pEcCas plasmid into LB, LB (Kana + )、LB(Spec + ) liquid culture medium for resistance verification; the genome was extracted using the Biotech Bacterial Genomic DNA Extraction Kit, and PCR amplification was performed using the KOD FX Neo enzyme of TOYOBO Biological, with primers UOX-up-F (SEQ ID NO: 7) and UOX-down-R (SEQ ID NO: 18). The amplified product was sent to Qingke Biological for sequencing verification, and the sequencing results were compared and analyzed using Sequencher software.

[0074] 4. Construction of EcN[PelB-UOX-2] strain with two urate oxidase expression cassettes inserted into the genome

[0075] 4.1 Overlap PCR to obtain the [PelB-UOX-2] expression cassette

[0076] A second uricase expression cassette [PelB-UOX-2] was inserted into the genome. The difference from the first expression cassette [PelB-UOX] is that the gene sequences of the upstream homologous fragment and the downstream homologous fragment are different. Its sequence needs to be determined based on the upstream and downstream genes of the non-coding region (1766918-1766937) between the second insertion site pntA and ydgH in the genome. The remaining elements including the promoter P32, signal peptide PelB, uricase UOX and terminator T1 are consistent with the first expression cassette. The upstream homologous fragment up2 (368 bp) and the downstream homologous fragment down2 (361 bp) were amplified using the EcN genome as a template; the promoter-signal peptide-uricase-terminator (P32-PelB-UOX-T1) was amplified using the pEcgRNA-N20[PelB-UOX] vector constructed in Experiment 1 as a template; and the [PelB-UOX-2] expression frame up2-P32-PelB-UOX-T1-down2 was obtained by overlapping PCR amplification, and the amplified product was purified using the full gold DNA gel rapid purification kit. Amplification was performed using 2×Platinum TM SuperFi TM IIPCR Master Mix high-fidelity enzyme, the amplification primers are shown in Table 3, and the gene sequences of the upstream homologous fragment up2 and the downstream homologous fragment down2 are shown in Table 4.

[0077] Table 3 Amplification primers

[0078]

[0079]

[0080] Table 4 Sequences of each fragment of [PelB-UOX-2] expression cassette

[0081]

[0082] 4.2 Construction of pEcgRNA-N20[PelB-UOX-2] vector

[0083] A second uricase expression cassette was inserted into the EcN genome, and its CRISPR target N20-2 (GGTAAAACGAGACATCGCCC) was located in the non-coding region between pntA and ydgH (1766918-1766937), and T4 ligated with the pEcgRNA vector to construct the pEcgRNA-N20-2 vector, and the implementation method was the same as in Example 1. The pEcgRNA-N20-2 restriction vector was homologously recombined with the [PelB-UOX-2] expression cassette to construct the pEcgRNA-N20-[PelB-UOX-2] vector, and the implementation method was the same as in Example 1.

[0084] 4.3. Construction of EcN[PelB-UOX-2] strain

[0085] The second uricase expression cassette [PelB-UOX-2] CRISPR was inserted into the genome: EcN [PelB-UOX] (containing pEcCas plasmid) strain was prepared into competent cells, and pEcgRNA-N20 [PelB-UOX-2] plasmid was transformed and spread on LB (Kana + Spec + ) medium, picked a single colony clone for colony PCR verification, and the primers were T1-F (SEQ ID NO: 15) and UOX-EcN-R-2 (SEQ ID NO: 30).

[0086] The specific steps of plasmid elimination, liquid culture resistance verification and genome amplification sequencing verification are as above.

[0087] Example 2 Construction of LPrihC vector and LPrihC strain and UOX-rihC combined strain.

[0088] Experimental reagents: Phanta high-fidelity enzyme (Nanjing Novogene Biotechnology), LB broth, HindIII-HF restriction endonuclease (New England Biolabs), BamHI restriction endonuclease (New England Biolabs), DL2000DNALadder, 2×Taq PCR Master Mix, QuickCut DpnI enzyme (Takara), DH5α competent state, carbenicillin (CB), ampicillin sodium salt (AMP), EasyGeno Assembly Cloning Kit homologous recombination kit (Tiangen Biochemical), DNA gel rapid purification kit, plasmid mini-extraction kit (Quanshijin).

[0089] 1. Synthesis of nucleoside hydrolase rihC gene sequence.

[0090] The full sequence of the rihC gene of Lactiplantibacillus plantarum was synthesized after codon optimization by Qingke Biotechnology, and a BamHI restriction site was added at the 5' end, and a histidine tag (6×His-Tag) and a HindIII restriction site were added at the 3' end, using pET-22b as the vector. Phanta high-fidelity enzyme was used to amplify the rihC gene fragment, the template was the pET-22b (rihC) plasmid, the amplification primers were shown in Table 5, and the fragments obtained by PCR amplification were shown in Table 6. The amplified products were purified using the full gold DNA gel rapid purification kit.

[0091] Table 5 Amplification primer sequences

[0092]

[0093]

[0094] Table 6 Gene sequence

[0095]

[0096] 2. Enzyme digestion of pLPP-OmpA vector.

[0097] The pLPP-OmpA strain purchased from Wuhan Xiangran Biotechnology Co., Ltd. was streaked and activated, and inoculated into LB (AMP) liquid culture for expansion. Plasmids were extracted using a plasmid mini-extraction kit, and the pLPP-OmpA vector was double-digested with BamHI restriction endonuclease and HindIII restriction endonuclease, and the digested products were purified using a full-form gold DNA gel rapid purification kit.

[0098] 3. Construction of LPrihC vector.

[0099] The Tiangen EasyGeno Assembly Cloning Kit homologous recombination kit was used to homologously recombinant the nucleoside hydrolase rihC gene (985bp) with the pLPP-OmpA restriction vector, and the DH5α competent cells were transformed. The positive clones were preliminarily verified by colony PCR, and amplified using 2×Taq PCR Master Mix. The amplification primers were RihC-con-F (SEQ ID NO: 33) and RihC-con-R (SEQ ID NO: 34), and the pLPP-OmpA vector was used as a negative control. The positive clones picked by colony PCR were shaken overnight, and the plasmids were extracted using the full-type gold plasmid mini-extraction kit for verification, with the pLPP-OmpA vector as a negative control; the positive clones with the correct plasmid size were double-digested with HindIII-HF restriction endonuclease and BamHI restriction endonuclease, with the pLPP-OmpA vector as a negative control, and the positive clone plasmids with the correct restriction verification were sent to Qingke Bio for sequencing. The sequencing primers were LLP-CON-F (SEQ ID NO: 35) and LLP-CON-R (TACGCGTGACGCAGTAGCGG) (SEQ ID NO: 36), and the sequencing results were compared and analyzed using Sequencher software.

[0100] 4. Construction of LPrihC strain.

[0101] The wild-type EcN strain was prepared into competent cells, transformed with the LPrihC plasmid, and plated on LB (CB) medium.

[0102] 5. Construction of UOX-rihC Combined Strain

[0103] The EcN[PelB-UOX-2] strain constructed in Example 1 was prepared into competent cells, transformed with the LPrihC plasmid, and spread on LB (CB) medium.

[0104] The PCR amplified rihC gene fragment (1014 bp) was Figure 3 As shown, the band sizes are as expected.

[0105] The results of colony PCR verification of LPrihC vector are as follows Figure 4 As shown in Figure 2, the positive clone connected to the nucleoside hydrolase rihC fragment can amplify a band of about 750 bp, while the original pLPP-OmpA vector used as a control does not have this specific band; the plasmid size detection results are shown in Figure 2. Figure 4 As shown, except for lane 14 (the 14th from the left) which is negative, all others are positive clones. The positive clone plasmid connected with the nucleoside hydrolase RihC fragment is significantly larger than the pLPP-OmpA vector; the results of double enzyme digestion using HindIII restriction endonuclease and BamHI restriction endonuclease are shown in FIG. Figure 4 As shown in the figure, the positive clone connected to the nucleoside hydrolase rihC fragment had two bands after restriction digestion, which were about 1000 bp and 7400 bp respectively. The negative control pLPP-OmpA vector had only one band of about 7400 bp after restriction digestion. The LPrihC vector with completely correct sequence was obtained by Sequencher analysis. The map of the LPrihC vector is shown in the figure Figure 5 shown.

[0106] The colonies in LB (CB) medium grew normally, and the colony morphology was Figure 6 As shown, the LPrihC strain is a milky white round colony with a smooth surface and neat and translucent colony edges.

[0107] The colonies in LB (CB) medium grew normally. The UOX-rihC strain was a round, milky white colony with a smooth surface and neat, translucent edges.

[0108] Example 3: Identification of expression of recombinant nucleoside hydrolase rihC in E. coli.

[0109] 1. Experimental reagents: PBS buffer, His Taq Antibody (Nanjing GenScript Biotechnology), Goat Anti-Mouse IgG (H&L) HRP (Shanghai Kanglang Biotechnology), 4× protein loading buffer, Rainbow 130 broad-spectrum protein marker, Running Buffer, Transfer Buffer (Nanjing GenScript Biotechnology), 10× TBST buffer, polyethylene glycol 8000, skim milk powder, methanol, BCA protein concentration determination kit, SDS-PAGE precast gel SurePAGE (8%-16%) 10 cells (Nanjing GenScript Biotechnology), PVDF membrane, dialysis bag, ECL detection kit (Jiangsu KeyGen Biotechnology).

[0110] 2. Strain protein extraction and BCA content determination.

[0111] The supernatant, periplasmic, intracellular soluble and inclusion body proteins of LPrihC strain and wild-type EcN strain (negative control) were extracted respectively, and the gradient dilution times (stock solution, 10 -1 , 10 -2 ), the protein content was determined using a BCA protein concentration assay kit, and the absorbance at 562 nm was measured by an enzyme marker to calculate the protein concentration.

[0112] 3. SDS-PAGE electrophoresis and Western-blot.

[0113] The protein loading amount of LPrihC strain and wild-type EcN strain (negative control) was 200 μg, added with 4× protein loading buffer, boiled in a boiling water bath for 10 min, loaded onto 8%-16% SDS-PAGE precast gel, added with Rainbow 130 broad-spectrum protein marker, and the voltage was 90 V for 15 min, and 130 V for 45 min.

[0114] Wet transfer was performed at 100 V for 50 min. After washing the membrane, 5% skim milk powder was used for blocking at room temperature for 2 h. The primary antibody (His Taq Antibody) was added at a ratio of 1:2500 and incubated at 4°C overnight. After washing the membrane, the secondary antibody (Goat Anti-Mouse IgG HRP) was added at a ratio of 1:7500 and incubated at room temperature for 2 h. The hybridization signal was detected by ECL kit and developed using Azure300 imager.

[0115] The supernatant, periplasmic, intracellular soluble and inclusion body proteins of the LPrihC strain and the wild-type EcN strain (negative control) were subjected to SDS-PAGE gel electrophoresis and Western-blot. Figure 7As shown, the negative control wild-type EcN strain does not express recombinant nucleoside hydrolase, the size of the recombinant nucleoside hydrolase rihC-histag (containing 6×His-Tag tag) is 34.94 kDa, and the recombinant nucleoside hydrolase exists in the cell.

[0116] Example 4: Purification of recombinant nucleoside hydrolase protein rihC by nickel column chromatography.

[0117] 1. Sample pretreatment.

[0118] The LPrihC strain and the wild-type EcN strain (negative control) were expanded and cultured (1 L), and the expression was induced by IPTG (final concentration 0.5 mM). After centrifugation, the bacteria were resuspended in binding buffer, and the cells were disrupted by ultrasound. After centrifugation, the cells were filtered through a 0.22 μm microporous membrane.

[0119] The chromatography system solution was prepared by mixing 20% ​​ethanol, binding buffer (20 mM sodium phosphate, 0.5 M sodium chloride, 25 mM imidazole, pH 7.4), and elution buffer (20 mM sodium phosphate, 0.5 M sodium chloride, 500 mM imidazole, pH 7.4). The solution was filtered through a 0.22 μm filter membrane and degassed by ultrasonication.

[0120] 2. Purification by nickel column chromatography.

[0121] The recombinant nucleoside hydrolase with a histidine tag (His-tag) was purified using the AutoPure protein purification chromatography system. The chromatography column was His Trap TM HP, the system injection flow rate was 5 mL / min, 15 column volumes were washed with binding buffer, and the elution buffer was used for one-step elution at a flow rate of 5 mL / min. 50% elution buffer (250 mM) and 100% elution buffer (500 mM) were used for one-step elution, respectively, and 5 column volumes were collected.

[0122] 3. Sample purification.

[0123] The purified protein was dialyzed using a dialysis bag, and the imidazole was first removed using PBS solution, and then concentrated using polyethylene glycol 8000.

[0124] Protein chromatography purification uses a one-step elution method, 250mM and 500mM respectively, and all components within the peak area are collected. The protein purification spectrum of the LPrihC strain is shown in Figure 8 As shown, most of the purified nucleoside hydrolase proteins elute in 250 mM elution buffer. The protein purification spectrum of the wild-type EcN strain is shown in Fig. 9 As shown, there is no chromatographic peak of the recombinant protein rihC-histag (containing 6×His-Tag tag).

[0125] Example 5: Determining the purification effect of the recombinant nucleoside hydrolase protein rihC.

[0126] 1. Strain protein extraction and BCA content determination.

[0127] The purified nucleoside hydrolase protein of LPrihC strain was diluted in gradient multiples (stock solution, 10 -1 , 10 -2 ), the protein content was determined using the BCA protein concentration determination kit of Wuhan Eliorite Biotechnology, and the absorbance at 562 nm was measured by an ELISA reader to calculate the protein concentration.

[0128] 2. SDS-PAGE electrophoresis.

[0129] The purified protein (250mM elution), purified protein (500mM elution), and unpurified protein samples of the LPrihC strain, and the purified protein and unpurified protein samples of the wild-type EcN strain were added with 4× protein loading buffer, boiled in a boiling water bath for 10 min, loaded onto 8%-16% SDS-PAGE precast gel, and Rainbow 130 broad-spectrum protein marker was added, and the voltage was 90V for 15min and 130V for 45min.

[0130] 3. Coomassie Brilliant Blue Staining.

[0131] Weigh 0.25 g of Coomassie Brilliant Blue R-250, add isopropanol, glacial acetic acid and ultrapure water to prepare Coomassie Brilliant Blue staining solution, and glacial acetic acid, anhydrous ethanol and ultrapure water to prepare Coomassie Brilliant Blue decolorizing solution.

[0132] Remove the PAGE gel after electrophoresis and place it in a container. Slowly shake the Coomassie Brilliant Blue staining solution at room temperature for 20 minutes. After discarding the staining solution, add the destaining solution and slowly shake it at room temperature for 15 minutes. After changing the destaining solution three times, leave it at room temperature overnight.

[0133] 4.Western-blot.

[0134] Wet transfer was performed at a voltage of 100 V for 50 min. The remaining steps were similar to the experimental method in Example 3.

[0135] Coomassie Brilliant Blue staining to identify protein purification results Fig.10 As shown, there are many protein bands before purification. There is a target band between 33-43kDa in the purified protein (250mM) in lane 2, while there is no such band in the purified protein of the wild-type EcN (negative control) strain. The chromatography system successfully purified the nucleoside hydrolase protein (6×His-tag) of the EcN-pLPP-OmpA[RihC] strain.

[0136] Western-blot protein purification results Fig.11As shown, the purified protein (250 mM) has a clear band between 33-43 kDa. Since the His-tag antibody only binds to the target protein (6×His-tag), there is no such band in other lanes.

[0137] Example 6: Detecting the nucleoside degradation effect of the recombinant nucleoside hydrolase protein rihC.

[0138] 1. HPLC solution preparation.

[0139] The inosine solution and the guanosine solution were prepared to 400 mg / L and filtered through a 0.22 μm microporous membrane.

[0140] Mobile phase preparation: 5.436 g potassium dihydrogen phosphate, 20 mL methanol, 1 mL phosphoric acid, dilute to 2 L with ultrapure water, adjust pH (3.5-3.62), filter with 0.2 μm organic filter membrane, and degas by ultrasonication.

[0141] 2. Nucleoside hydrolase purification protein nucleoside degradation detection.

[0142] Take 750 μL of the chromatographically purified nucleoside hydrolase protein and resuspend it with 750 μL of inosine and guanosine solution. Use the wild-type EcN purified protein as a negative control. Take samples at 0 h and 6 h, heat in a 95°C water bath for 10 min to inactivate, centrifuge at 10,000 rpm for 10 min, take the supernatant and filter it with a 0.22 μm microporous membrane, and measure it with a high performance liquid chromatography.

[0143] The purified protein of nucleoside hydrolase was degraded by reaction with nucleoside for 6 hours. The degradation rate comparison results are as follows: Fig.12 The results of inosine content determination are shown in Fig.13 As shown, the degradation rate of the blank control group was 0.00%, the degradation rate of inosine in the purified protein (250 mM) of the LPrihC strain was 100%, and the degradation rate of inosine in the purified protein (500 mM) was 5.05%; the results of the guanosine content determination are shown in Fig.14 As shown, the degradation rate of the blank control group was 0.00%, the degradation rate of guanosine of the purified protein (250 mM) was 100%, and the degradation rate of guanosine of the purified protein (500 mM) was 9.94%. The recombinant nucleoside hydrolase mainly existed in the 250 mM imidazole eluent and could effectively reduce the content of inosine and guanosine in the solution.

[0144] Example 7: Detection of the nucleoside degradation effect of the engineered bacterium UOX-rihC.

[0145] 1. HPLC solution preparation. For detailed preparation method, see Example 6.

[0146] 2. Nucleoside degradation detection.

[0147] Guanosine degradation: Take 4 mL of UOX-rihC bacterial culture (OD 600 The mixture was centrifuged at 8000 rpm for 7 min, and the cells were washed once with 1 mL of PBS buffer. The cells were resuspended in 750 μL of PBS buffer and 750 μL of guanosine solution (1.3 mM, final concentration 200 mg / L) were added. The cells were reacted in a 1.5 mL EP tube and cultured in a shaking incubator at 37°C and 200 rpm.

[0148] Inosine degradation: The steps are the same as above, 750 μL of inosine solution (1.3 mM, final concentration 200 mg / L) was added, reacted in a 1.5 mL EP tube, and cultured in a shaking incubator at 37° C. and 200 rpm.

[0149] Sampling was performed at 0 h, 3 h, and 6 h, and the samples were heated in a 95°C water bath for 10 min for inactivation. The samples were centrifuged at 10,000 rpm for 10 min, and the supernatant was filtered through a 0.22 μm microporous filter membrane and measured by high performance liquid chromatography.

[0150] The whole cells of the UOX-rihC strain were degraded by reaction with inosine and guanosine for 6 h, and the inosine content was determined as Fig.15 As shown, the degradation rate of the blank control group was 0.00%, the degradation rate of inosine by the UOX-rihC strain was 100%, and the degradation trend of guanosine was as shown in Fig.16 As shown, the degradation rate of the blank control group was 0.00%, and the guanosine degradation rate of the UOX-rihC strain was 100%. The whole cells of the UOX-rihC strain can effectively reduce the content of inosine and guanosine in the solution.

[0151] Example 8: Detecting the uric acid degradation effect of the engineered bacteria UOX-rihC.

[0152] 1. HPLC solution preparation.

[0153] The uric acid solution was prepared to 150 mg / L and filtered through a 0.22 μm microporous membrane. The detailed preparation method of the mobile phase is shown in Example 6.

[0154] 2. Uric acid degradation detection.

[0155] Take 20 mL of UOX-rihC bacterial suspension (OD 600 Adjust to 2.0), centrifuge at 8000rpm for 7min, add 10mL PBS buffer to wash once, resuspend with 4mL uric acid solution, react in 50mL centrifuge tube, take samples at 0h, 6h, and 24h, heat in a 95℃ water bath for 10min to inactivate, centrifuge at 10000rpm for 10min, take the supernatant and filter with 0.22μm microporous membrane, and measure by high performance liquid chromatography.

[0156] The whole cells of the UOX-rihC strain reacted with uric acid for 24 hours and the degradation trend of uric acid was as follows: Fig.17 As shown, the degradation rate of the blank control group was 0.00%, and the 24h uric acid degradation rate of the UOX-rihC strain was 28.9%. The whole cells of the UOX-rihC strain can effectively reduce the uric acid content in the solution.

[0157] Example 9: Comparison of the inosine degradation effects of the combined strain UOX-rihC and the single gene strain LPrihC.

[0158] 1. HPLC solution preparation. For detailed preparation method, see Example 6.

[0159] 2. Nucleoside degradation detection.

[0160] Take 4 mL of UOX-rihC bacterial suspension (OD 600 The cell culture medium was centrifuged at 8000 rpm for 7 min, and the cells were washed once with 1 mL of PBS buffer. The cells were resuspended with 750 μL of PBS buffer and 750 μL of inosine solution (1.3 mM, final concentration 200 mg / L) were added. The cells were reacted in a 1.5 mL EP tube and cultured in a shaking incubator at 37°C and 200 rpm.

[0161] Take 2 mL of LPrihC bacterial solution (OD 600 Adjusted to 2.0) and 2 mL of EcN[PelB-UOX-2] bacterial solution (OD 600 The mixture was mixed and centrifuged at 8000 rpm for 7 min. The cells were washed once with 1 mL of PBS buffer and resuspended with 750 μL of PBS buffer. Then, 750 μL of inosine solution (1.3 mM, final concentration 200 mg / L) was added and reacted in a 1.5 mL EP tube. The cells were cultured in a shaking incubator at 37°C and 200 rpm.

[0162] At the same time, the wild-type EcN strain was used as the negative control group, and the operation steps were the same as above.

[0163] Sampling was performed at 0 h and 6 h, and the samples were heated in a 95°C water bath for 10 min to inactivate the samples. The samples were centrifuged at 10,000 rpm for 10 min, and the supernatant was filtered through a 0.22 μm microporous membrane and measured by high performance liquid chromatography.

[0164] The whole cells of the UOX-rihC strain were reacted with inosine for 6 h, and the inosine content was determined as Fig.18As shown, the degradation rate of the blank control was 0.00%, the degradation rate of the wild-type EcN strain was 21.22%, the degradation rate of the mixed bacterial liquid LPrihC+EcN[PelB-UOX-2] was 38.16%, and the degradation rate of the combined strain UOX-rihC was 68.68%. The effect of the combined strain was better than that of the mixed strain of single gene strains (68.68%>38.16%), indicating that in the combined strain UOX-rihC, the UOX gene and rihC can play a synergistic role and jointly improve the degradation rate of inosine.

[0165] In summary, the advantages of Escherichia coli E. coli Nissle 1917 (EcN) are very prominent, including outstanding probiotic properties and easy genetic manipulation. Specifically, this strain is non-pathogenic (serotype O6: K5: H1), has antagonistic activity against enteric pathogens such as Shigella, Vibrio cholerae, Salmonella enteritidis, and invasive Escherichia coli, and has sufficient molecular biology toolboxes for EcN engineering. In addition, this bacterium is genetically stable and will not be transformed by phagocytes of enterohemorrhagic Escherichia coli strains. It can also produce defensins, cathelicidins, and calprotectins, which have anti-inflammatory effects. Live EcN bacteria show robustness in the mammalian gastrointestinal tract, and a variety of biological treatment strategies based on EcN vectors are feasible.

[0166] The present invention constructs a vector for expressing recombinant nucleoside hydrolase, adds a BamHI restriction site at the 5' end of the Lactobacillus plantarum nucleoside hydrolase rihC gene sequence, adds a HindIII restriction site at the 3' end, and performs homologous recombination by enzyme cleavage of the pLPP-OmpA vector to construct an LPrihC strain expressing nucleoside hydrolase, and HPLC verifies that the induced expressed protein can effectively degrade inosine and guanosine after purification, thereby reducing the intestinal absorption of nucleosides, thereby leading to a decrease in the concentration of uric acid in the blood. Further, urate oxidase is inserted into the EcN genome, the engineered bacteria containing urate oxidase are made competent, and the vector expressing the recombinant nucleoside hydrolase is transformed therein to enable it to express urate oxidase, and HPLC verifies that the whole cell of the engineered bacteria strain can effectively degrade uric acid. When the expression protein genes of urate oxidase and nucleoside hydrolase are constructed on the same strain, both uric acid and inosine can be degraded, and the inosine degradation effect of the combined strain is better than that of a mixture of single-gene strains. The application of purified recombinant protein of nucleoside hydrolase or combined engineered bacteria to the intestine has positive significance for the treatment of hyperuricemia.

[0167] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for constructing a nucleoside hydrolase and uricase combined with an engineered bacterium, characterized in that: The following steps are involved: S1, codon optimization of the nucleoside hydrolase rihC gene sequence, the optimized sequence is as shown in SEQ ID NO: 37; S2, homologous recombination of the optimized nucleoside hydrolase rihC gene sequence with the pLPP-OmpA plasmid vector to construct the LPrihC plasmid; S3, transforming the LPrihC plasmid into uricase oxidase engineering bacteria to construct the nucleoside hydrolase uricase oxidase combined engineering bacteria.

2. The method for constructing a nucleoside hydrolase and uricase oxidase-combined engineering bacterium according to claim 1, characterized in that: The optimized nucleoside hydrolase rihC gene sequence has a BamHI restriction site at the 5' end and a histidine tag (6×His-Tag) and a HindIII restriction site at the 3' end.

3. The method for constructing a nucleoside hydrolase and uricase-oxidase-combined engineering bacterium according to claim 1, characterized in that: The method for constructing the uricase engineering bacteria comprises the following steps: (1) The sequence of the urate oxidase encoding gene UOX was codon optimized, and the optimized sequence was shown in SEQ ID NO:4; the sequence of the signal peptide PelB was optimized, and the optimized sequence was shown in SEQ ID NO:3; (2) Using overlapping PCR technology to construct the urate oxidase expression cassette; (3) The CRISPR / Cas9 system is used to integrate the uricase expression frame into the genome of the chassis strain to construct the uricase oxidase engineered bacteria.

4. The method for constructing a nucleoside hydrolase and uricase oxidase-combined engineering bacterium according to claim 3, characterized in that: The chassis strain is EcN bacteria.

5. The method for constructing a nucleoside hydrolase and uricase-oxidase-combined engineering bacterium according to claim 3, characterized in that: The uricase expression frame is integrated into the non-coding region between the sites uspG and rnk (689269-689288) and the non-coding region between pntA and ydgH (1766918-1766937) in the genome of the chassis strain EcN bacteria.

6. The method for constructing a nucleoside hydrolase and uricase-oxidase-combined engineering bacterium according to claim 3, characterized in that: The promoter for constructing the uricase expression cassette is P32, whose sequence is shown in SEQ ID NO:2, and the terminator is T1, whose sequence is shown in SEQ ID NO:

5.

7. A nucleoside hydrolase and uricase combined engineering bacterium constructed by the method according to any one of claims 1 to 6.

8. Use of the nucleoside hydrolase uricase oxidase combined with the engineered bacteria according to claim 7 in the preparation of a drug for treating hyperuricemia.